Pharmaceuticals, Biotechnology & Life Sciences

Tonix Pharmaceuticals: pioneering CNS disorder therapies for fibromyalgia and PTSD, growing R&D pipeline and investor resilience despite market volatility.

Discover how Kuros Biosciences AG, a Swiss biotech leader, innovates orthobiologics to repair bone defects and advance regenerative spinal therapies worldwide.

New securities‑fraud lawsuit hits San Francisco‑based Nektar Therapeutics, probing its drug‑development claims and financial woes while investors weigh the fallout.

Orthocell Ltd’s biotech focus on tendon & ligament repair faces major financial risks, with a negative P/E and falling stock—investors must weigh innovation against profitability.

Amplia Therapeutics: Melbourne‑based biotech innovating immuno‑oncology drugs to fight cancer—high‑risk, high‑reward investments with global impact.

Equillium Inc. earns a “Strong Buy” from Raymond James, boosting investor confidence as its autoimmune pipeline shows promise and may lift stock prices.

Vanda Pharmaceuticals faces a tough road: negative earnings, a steep stock drop, and a -1.96 P/E ratio, yet its CNS‑focused drugs keep investors on edge for breakthrough therapies.

ProText Mobility’s botanical drug innovation faces steep financial hurdles: a declining stock, negative P/E, and OTC listing challenge its future growth prospects.

SoftOx Solutions AS secures private placement to fund its biofilm‑eradication drugs, boosting capital for next‑stage trials and infection‑treatment breakthroughs.

Almirall SA’s stock volatility and high P/E signal a risky investment, even as the Spanish pharma firm’s dermatology focus may limit growth amid fierce competition.